Fierce Biotech reports that Japan's Takeda will set aside 50 billion Yen per year for the next 3 years to fund the acquisition of new products for its portfolio. That's 50 billion incremental Yen to what it normally sets aside for this purpose.
Got a new drug to sell? You now have another company to call!
Posted by Bruce Lehr July 9th 2010.